Drugs / Visanne
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00225199 | Mar 2004 → Sep 2006 | endometriosis | Bayer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05013242 Comparator | Dec 2020 → Nov 2021 | endometriosis | Mansoura University | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-12-20 | Bayer | Bayer receives approval in China for endometriosis treatment Visanne™ bayer.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Visanne | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00225199 ↗ |
| Known as | BAY86-5258 | “Visanne (BAY86-5258, SH T00660AA)” NCT00225199 ↗ |
| Known as | SH T00660AA | “Visanne (BAY86-5258, SH T00660AA)” NCT00225199 ↗ |
| Route | Oral | “Visanne (dienogest 2mg) oral once daily for 12 weeks” NCT05013242 ↗ |